Journal:
Article Title: Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans
doi: 10.1128/AAC.45.7.2018-2022.2001
Figure Lengend Snippet: Amphotericin B, flucytosine, and {"type":"entrez-nucleotide","attrs":{"text":"LY303366","term_id":"1257625064"}} LY303366 susceptibilities of ATCC 90028 and 21 clinical isolates of C. albicans in RPMI and in human serum
Article Snippet: {"type":"entrez-nucleotide","attrs":{"text":"LY303366","term_id":"1257625064"}} LY303366 MICs for all 10 isolates tested were 8- to 32-fold higher in serum than in RPMI. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Isolate MIC (μg/ml) Fluconazole Itraconazole Ketoconazole Fluconazole susceptible ATCC 90028 RPMI 0.25 0.03 0.125 Serum 0.25 0.25 0.25 JK23 RPMI 8 0.25 0.5 Serum 2 2 2 JK27 RPMI 4 0.125 0.25 Serum 2 2 1 2-76 RPMI 0.25 0.03 0.125 Serum 0.25 1 0.5 Fluconazole susceptible, dose dependent CA12 RPMI 32 1 1 Serum 2 1 1 JK1 RPMI 32 2 1 Serum 8 4 2 JK9 RPMI 32 1 1 Serum 8 2 2 TO16 RPMI 32 2 1 Serum 16 4 4 Fluconazole resistant CA38 RPMI 128 1 2 Serum 32 4 4 JK13 RPMI 128 2 0.5 Serum 64 2 4 JK28 RPMI >128 16 >16 Serum 4 2 1 JK31 RPMI 128 0.5 0.5 Serum 0.25 0.5 0.5 JK32 RPMI 64 0.5 0.5 Serum 16 1 2 JK37 RPMI 128 0.5 0.5 Serum 0.25 0.5 0.5 TO1 RPMI 128 4 4 Serum 0.25 0.5 0.5 TO3 RPMI 128 4 8 Serum 32 16 16 TO5 RPMI 64 1 1 Serum 64 8 16 TO6 RPMI 64 1 1 Serum 32 8 8 TO8 RPMI >128 2 8 Serum 64 2 8 TO10 RPMI >128 >16 16 Serum 1 1 0.5 TO17 RPMI 64 1 4 Serum 16 4 8 12-99 RPMI 64 0.25 1 Serum 32 8 4 Open in a separate window Azole susceptibilities of ATCC 90028 and 21 clinical isolates of C. albicans in RPMI and in serum table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Isolate MIC (μg/ml) Amphotericin B Flucytosine {"type":"entrez-nucleotide","attrs":{"text":"LY303366","term_id":"1257625064"}} LY303366 ATCC 90028 RPMI 1 0.5 0.125 Serum 1 2 1 CA38 RPMI 2 0.125 0.25 Serum 2 0.25 2 JK23 RPMI 1 0.25 0.25 Serum 1 0.5 2 JK27 RPMI 1 0.25 0.25 Serum 1 0.5 2 JK28 RPMI 1 0.5 0.125 Serum 1 1 1 JK32 RPMI 1 1 0.125 Serum 1 1 1 TO3 RPMI 1 0.125 0.125 Serum 1 0.5 1 TO17 RPMI 1 0.125 0.125 Serum 1 0.5 1 2-76 RPMI 1 0.25 0.125 Serum 1 1 1 12-99 RPMI 1 1 0.125 Serum 1 2 4 Open in a separate window Amphotericin B, flucytosine, and {"type":"entrez-nucleotide","attrs":{"text":"LY303366","term_id":"1257625064"}} LY303366 susceptibilities of ATCC 90028 and 21 clinical isolates of C. albicans in RPMI and in human serum The influence of RPMI supplemented with BSA (50 mg/ml) on MICs was tested for 10 isolates (ATCC 90028, CA38, JK23, JK27, JK28, JK32, TO3, TO17, 2-76, and 12-99).
Techniques:
ATCC is a verified supplier 
ATCC manufactures this product 
